Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8343290 | 1.00 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1491238 | 1.00 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1273196 | 0.81 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14274222 | 0.77 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6631971 | 0.77 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20141501 | 0.74 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20141503 | 0.74 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20141502 | 0.74 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL254548 | 0.73 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Furan SCHEMBL7495514 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404680-A2 | PROCESS FOR PREPARING INTERMEDIATES OF HIV PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-04-07 | — | — | EP | claimed |
| US-20040026230-A1 | Process for preparing intermediates of hiv protease inhibitors | GLAXO GROUP LIMITED (GB) | 2004-02-12 | — | — | US | claimed |
| WO-2002067239-A2 | PROCESS FOR PREPARING INTERMEDIATES OF HIV PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | claimed |
| WO-2002060905-A2 | PROCESS FOR PREPARING INTERMEDIATES OF HIV PROTEASE INHIBITORS | GLAXO GROUP LTD (GB) | 2002-08-08 | — | — | WO | claimed |
| US-9889115-B2 | Fitness assay and associated methods | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2336134-B1 | Fitness assay and methods for reducing resistance of HIV to therapy | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2570416-B1 | Antiviral bisfuran derivative as hiv protease inhibitor and intermediates thereof | GILEAD SCIENCES INC (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-1088098-B2 | FITNESS ASSAY AND METHODS FOR REDUCING RESISTANCE OF HIV TO THERAPY | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140011815-A1 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-01-09 | — | — | US | disclosed |
| US-8597876-B2 | Method of treating HIV infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-12-03 | — | — | US | disclosed |
| EP-1999133-B1 | PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS | GILEAD SCIENCES INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130172295-A1 | PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2003078438-A1 | CARBAMATES AS HIV PROTEASE INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2002067239-A2 | PROCESS FOR PREPARING INTERMEDIATES OF HIV PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002060905-A2 | PROCESS FOR PREPARING INTERMEDIATES OF HIV PROTEASE INHIBITORS | GLAXO GROUP LTD (GB) | 2002-08-08 | — | — | WO | disclosed |
| EP-1088098-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND SOCIAL SERVICES (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067254-A2 | MULTI-DRUG RESISTANT RETROVIRAL PROTEASE INHIBITORS AND USE THEREOF | THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067417-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | disclosed |
| US-4855318-A | OF 1,3-DIOXOLANES OR -DIOXANES, OR TETRAHYDROFURANS OR -PYRANS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | disclosed |
| US-4719227-A | Iodopropargyl cyclic ethers useful as Microbicidal agents | BAYER AKTIENGESELLSCHAFT (DE) | 1988-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172295-A1 | PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS | PRSS1, PREP, SERPINB1 | CHRM2 4884/4885CHRM4 4841/4885CHRM5 4833/4885 |
| US-20140011815-A1 | FITNESS ASSAY AND ASSOCIATED METHODS | CPS1, CTSS, TST | CHRM2 2349/4885CHRM4 2665/4885CHRM5 2876/4885 |
| US-20040026230-A1 | Process for preparing intermediates of hiv protease inhibitors | PREP, FURIN, RCE1 | CHRM2 4873/4885CHRM4 4766/4885CHRM5 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.